about
Immunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsTargeted drug delivery via folate receptors in recurrent ovarian cancer: a reviewRisk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriersCO2 laser therapy of the Bartholin's gland cyst: surgical data and functional short- and long-term results.Chemotherapy in elderly patients with gynecological cancer.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.Nonabsorbable suture granuloma mimicking ovarian cancer recurrence at combined positron emission tomography/computed tomography evaluation: a case reportCO2 laser treatment for Bartholin gland abscess: ultrasound evaluation of risk recurrence.Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.Late aortic lymphocele and residual ovary syndrome after gynecological surgery.Solitary gastric recurrence from ovarian carcinoma: a case report and literature review.Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.First-line treatment of advanced ovarian cancer: current research and perspectives.Limits of ¹⁸F-fluorodeoxyglucose positron emission tomography in recurrence diagnosis of borderline ovarian tumor.Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: case report and literature review.Role of chemotherapy in the management of vulvar carcinoma.Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.Olaparib, PARP1 inhibitor in ovarian cancer.Hormone therapy in oophorectomized BRCA1/2 mutation carriers.Surgical treatment of an isolated omental cervical cancer recurrence: report of a case and review of the literature.The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis.Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).Perivascular epithelioid cell neoplasm (PEComa) of the uterus: A systematic review.An overview of early investigational therapies for chemoresistant ovarian cancer.Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.Cediranib in ovarian cancer: state of the art and future perspectives.Ixabepilone for the treatment of endometrial cancer.Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis.A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: a multicentric Italian experience.Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery.Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy.Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.
P50
Q26799812-77611A32-E4E4-4007-8F8B-83C94F3F81B4Q26828581-AF9E54EE-3D64-492C-9EC5-4F9D152B6F29Q27003935-A6CDFB90-0570-48E2-ADD5-B971147E3A3CQ31111545-DA7FD50E-028E-4284-B560-E1556383AF64Q33410185-272FDE48-814A-4D11-9FC0-EB63FB18290BQ33413609-E9CBCE58-EED7-4025-8C22-99E80819290DQ33846891-3C20F94A-0787-4498-B32B-25BF4226906CQ34574086-1F6664DC-1AC3-4FB7-8A9E-63136E4978F0Q35682766-4652D1C4-B30A-408D-98ED-08E247D08A3CQ36489301-9070820F-6B56-44F0-A7A9-F463BEDC7392Q36805494-AC9B6D27-8AED-4767-BA14-8F50A703AEF7Q37022434-E1CAD843-02E2-4AB7-BFAF-FAE16618C9E7Q37294314-239F158C-6242-42D6-A5F2-297A133A9C85Q37629090-0024D25A-21DC-4E0B-A1E3-205C4468B1E7Q37656214-29614091-C566-4AE9-AA93-44C5C804B428Q37802825-74200381-EF8A-4A77-AB15-135E5E967CA4Q37848725-1520D761-BD25-43F9-8DDB-F87FF9D4184BQ37878049-E2E2ED0C-EF1A-44F5-BF4A-1CB290DA0CF1Q37953105-5F008AF1-727F-41A7-A426-713DE2B1BFAAQ38025738-D843DF4D-493F-4F80-A01D-DF1110E212B7Q38164226-4141AE2C-442B-4065-BB66-D4399C4A8973Q38213889-D7CD9107-4E0D-443A-BD22-3C58672BF4FFQ38236206-4975D12C-B23A-447D-8951-2F02774ABAA2Q38382072-A9E25BAA-8026-4187-8961-334723621A09Q38485072-B5BECD73-0A82-4A7B-AF5E-A0EECBE898F7Q38553247-39F66115-7191-4B43-880D-6CDE6BCD2F0FQ38630990-77F41676-0B0F-49E4-9015-488974A08AC9Q38691226-9C830C70-CE6C-4634-AEAB-187DDB6DBB6FQ38692683-E933462B-56A8-40FF-A54F-90D204E8A9FDQ38763500-29439A4C-9654-49C5-B47D-8A0D1D4D3530Q40285797-F0EEC6D7-2B71-4871-B3AF-B40078E01724Q40661470-4E6E4201-69F7-466A-878D-5F02ED3FA4A3Q41161920-507CDAE3-4C17-4186-AC3E-2A27051C8C10Q41174367-3446D29C-F9C0-452B-BC28-DAD17A1ADB21Q42552179-E14FA83D-31AF-4116-B5DD-4989B22F00F8Q44247526-33DC2480-8DDD-4046-A4C2-B052F74A5B8BQ45165398-FEAEBCC0-FE4F-480A-967F-D63B409BFCC7Q45906655-D6099C8D-B70B-49E0-AE01-610E98A72725Q47678068-36AEDB51-5B98-4047-AFE5-8CEE2255930BQ49023663-F8B55DE5-D325-4A99-B748-92A1C23504F4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudia Marchetti
@ast
Claudia Marchetti
@en
Claudia Marchetti
@es
Claudia Marchetti
@nl
Claudia Marchetti
@sl
type
label
Claudia Marchetti
@ast
Claudia Marchetti
@en
Claudia Marchetti
@es
Claudia Marchetti
@nl
Claudia Marchetti
@sl
prefLabel
Claudia Marchetti
@ast
Claudia Marchetti
@en
Claudia Marchetti
@es
Claudia Marchetti
@nl
Claudia Marchetti
@sl
P106
P1153
16242013300
P21
P31
P496
0000-0001-7098-8956